EP Patent

EP4001273A2 — Aminopyrimidines as alk inhibitors

Assigned to University of Michigan System · Expires 2022-05-25 · 4y expired

What this patent protects

The present disclosure provides compounds represented by Formula I : and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined as set forth in the specification. The presen…

USPTO Abstract

The present disclosure provides compounds represented by Formula I : and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4001273A2
Jurisdiction
EP
Classification
—
Expires
2022-05-25
Drug substance claim
No
Drug product claim
No
Assignee
University of Michigan System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.